Volume 88 Issue 39 | pp. 36-39
Issue Date: September 27, 2010

JAK Hammers

ACS Meeting News: JAK2 inhibitors show promise at knocking down the symptoms of rare blood cancers
Department: Business
Keywords: JAK2, myeloproliferative diseases, myelofibrosis, blood cancer

What a difference an amino acid makes. Five years ago, researchers noticed that many patients with rare blood cancers called myeloproliferative neoplasms, or MPNs, had a phenylalanine in place of a valine residue at a specific position on JAK2, a protein kinase involved in blood cell development. The discovery set off a hunt for molecules that could block the errant enzyme and thereby quash the diseases.

Today, a handful of JAK2 inhibitors have reached early . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society